Altimmune (ALT) Interest Coverage Ratio Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.06% |
| Dec 31, 2025 | 64.06% |
| Sep 30, 2025 | 65.03% |
| Jun 30, 2025 | 56.49% |
| Mar 31, 2025 | -41.28% |
| Sep 30, 2024 | 22.65% |
| Jun 30, 2024 | -41.31% |
| Mar 31, 2024 | -53.47% |
| Dec 31, 2023 | -139.19% |
| Sep 30, 2023 | -99.97% |
| Jun 30, 2023 | -26.05% |
| Mar 31, 2023 | -9.57% |
| Dec 31, 2022 | 15.10% |
| Sep 30, 2022 | 50.64% |
| Jun 30, 2022 | -50.02% |
| Mar 31, 2022 | -33.37% |
| Dec 31, 2021 | 21.76% |
| Sep 30, 2021 | -14.60% |
| Jun 30, 2021 | -46.66% |
| Mar 31, 2021 | -0.72% |
| Dec 31, 2020 | -104.35% |
| Sep 30, 2020 | -116.91% |
| Jun 30, 2020 | -106.59% |
| Mar 31, 2020 | -144.03% |
| Sep 30, 2019 | -180.98% |
| Jun 30, 2019 | -196.59% |
| Dec 31, 2018 | -26.71% |
| Sep 30, 2018 | 7.36% |
| Jun 30, 2018 | -185.90% |
| Mar 31, 2018 | -263.01% |
| Dec 31, 2017 | -246.59% |
| Sep 30, 2017 | -283.54% |
| Jun 30, 2017 | -25.82% |
| Mar 31, 2017 | 32.33% |
| Dec 31, 2016 | -49.27% |
| Sep 30, 2016 | -10.84% |
| Jun 30, 2016 | 3.88% |
| Mar 31, 2016 | -32.36% |
| Dec 31, 2015 | -131.53% |
| Sep 30, 2015 | -116.13% |
| Jun 30, 2015 | -89.79% |